Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma with Carfilzomib Lenalidomide Dexamethasone (CRD)
What is the purpose of this trial?
The primary objective of this study is to compare the detection rate of residual/refractory disease based on standard bone marrow biopsy versus guided myeloma lesion biopsy after induction therapy with carfilzomib, lenalidomide and dexamethasone regimen.
- Trial withYale Cancer Center
- Start Date05/28/2020
- End Date12/31/2021
- Last Updated08/15/2021
- Study HIC#2000021421